Adult Dosing
Acute exacerbations of chronic bronchitis
Community-acquired pneumonia
Pharyngitis and tonsillitis
Uncomplicated skin and skin structure infections
Note: Cefditoren tab. should be taken with meals
Pediatric Dosing
Acute exacerbations of chronic bronchitis
- >12 yrs: 400 mg PO bid x10 days
Community-acquired pneumonia
- >12 yrs: 400 mg PO bid x2wks
Pharyngitis and tonsillitis
- >12 yrs: 200 mg PO bid x10 days
Uncomplicated skin and skin structure infections
- >12 yrs: 200 mg PO bid x10 days
Note: Cefditoren tab. should be taken with meals
- Safety and effectiveness in pediatric patients <12 yrs have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Mild renal impairment (50-80 mL/min/1.73 m2): No dose adjustments
- Moderate renal impairment (30-49 mL/min/1.73 m2): Max: 200 mg bid
- Severe renal impairment (<30 mL/min/1.73 m2): Max: 200 mg qd
- ESRD: Dose adjustments not defined
Hepatic Dose Adjustment
- Mild-moderate hepatic impairment (Child-Pugh Class A or B): No dose adjustments
- Severe hepatic impairment (Child-Pugh Class C): Dose adjustments not defined
- Prior to initiating therapy, determine whether the patient has a history of hypersensitivity to cefditoren, cephalosporins, penicillins or other drugs to avoid cross-hypersensitivity reactions
- Discontinue therapy if an allergic reaction occurs and institute proper treatment
- If diarrhea occurs during therapy, evaluate for pseudomembranous colitis as it may be associated with cefditoren use
- It may alter normal flora of the colon and may permit overgrowth of clostridia resulting in Clostridium difficile-associated colitis
- Discontinue therapy in mild cases of pseudomembranous colitis. Manage with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis, in moderate to severe cases
- Avoid use in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication as it may increase the risk of the development of drug-resistant bacteria rather than providing benefit to the patient
- Chronic use may manifest carnitine deficiency. Therefore short-term use is recommended
- Monitor for serum carnitine concentrations during cefditoren therapy especially in patients with renal impairment, patients with decreased muscle mass
- If superinfection occurs during therapy, appropriate alternative therapy should be administered
- Cefditoren may decrease prothrombin activity. Monitor prothrombin time in patients with renal or hepatic impairment, poor nutritional state, long term antimicrobial use, and in those previously stabilized on anticoagulant therapy
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Hypersensitivity to penicillins
- Hx of antibiotic-associated colitis
Pregnancy Category:B
Breastfeeding: Safety unknown. Cefditoren is acceptable to use during breastfeeding as cephalosporins are generally not expected to cause adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 December 2010). Manufacturer advises caution while administering to a nursing woman.
Pricing data from www.DrugStore.com in U.S.A.
- Spectracef 200 MG TABS [Bottle] (CORNERSTONE BIOPHARMA)
60 mg = $342.01
180 mg = $992.02 - Spectracef 200 MG TABS [Disp Pack] (CORNERSTONE BIOPHARMA)
20 mg = $299.98
40 mg = $575.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
